1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis
暂无分享,去创建一个
Christopher B. Cooper | S. Narayanan | C. Cooper | K. Mdluli | V. Ramachandran | R. Shandil | C. Sadler | Sreevalli Sharma | Pravin S. Shirude | J. Reddy | Vijender Panduga | P. Iyer | S. Solapure | M. Chatterji | M. Manjunatha | Naveen V Kumar | Ramanatha Saralaya | Prabhakar Kr
[1] T. Buclin,et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones , 2014, EMBO molecular medicine.
[2] Vijay T. Ahuja,et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. , 2013, Journal of medicinal chemistry.
[3] V. Mizrahi,et al. Complex genetics of drug resistance in Mycobacterium tuberculosis , 2013, Nature Genetics.
[4] P. Brennan,et al. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. , 2013, Future microbiology.
[5] Peter G. Schultz,et al. University of Birmingham Identification of a small molecule with activity against drug-resistant and persistent tuberculosis , 2013 .
[6] Vijay T. Ahuja,et al. In Vitro and In Vivo Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.
[7] S. Cole,et al. In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.
[8] Douglas Ferguson,et al. Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[9] K. Floyd,et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments , 2012, The Lancet.
[10] S. Bharath,et al. Aerosol Infection Model of Tuberculosis in Wistar Rats , 2010, International journal of microbiology.
[11] M. Raviglione,et al. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes , 2010, Current opinion in pulmonary medicine.
[12] Stewart T. Cole,et al. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.
[13] E. Rubin,et al. Bacterial Growth and Cell Division: a Mycobacterial Perspective , 2008, Microbiology and Molecular Biology Reviews.
[14] P. Tonge,et al. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. , 2008, Accounts of chemical research.
[15] P. Brennan,et al. Decaprenylphosphoryl Arabinofuranose, the Donor of the d-Arabinofuranosyl Residues of Mycobacterial Arabinan, Is Formed via a Two-Step Epimerization of Decaprenylphosphoryl Ribose , 2005, Journal of bacteriology.